Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O76080

UPID:
ZFAN5_HUMAN

ALTERNATIVE NAMES:
Zinc finger A20 domain-containing protein 2; Zinc finger protein 216

ALTERNATIVE UPACC:
O76080; A8K484

BACKGROUND:
The AN1-type zinc finger protein 5, identified by its alternative names Zinc finger A20 domain-containing protein 2 and Zinc finger protein 216, is integral to the ubiquitin-proteasome system for protein degradation. It functions by anchoring ubiquitinated proteins to the proteasome, essential in muscle atrophy and regulating NF-kappa-B activation and apoptosis. Its inhibition of NF-kappa-B activation, triggered by various factors including RIPK1 and TRAF6, alongside its role in sensitizing cells to TNF-induced apoptosis, highlights its regulatory significance. Additionally, it serves as a potent inhibitor of osteoclast differentiation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of AN1-type zinc finger protein 5 unveils potential avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.